Former Executive Vice President, Chief Financial Officer · Supernus Pharmaceuticals, Inc. (SUPN)

James Kelly

FY2020 is the first fiscal year CompBrief holds for James Kelly as a named executive officer of Supernus Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,801,636

Salary $102,910Stock awards $0

2nd of 6 named executive officers at Supernus Pharmaceuticals by FY2020 total.

6 named officers on file for Supernus Pharmaceuticals, FY2020

James Kelly’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 3 equity grants, each cited to its filing
  • SUPN’s disclosed peer group of 29 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Supernus Pharmaceuticals’s whole pay program stands against its peers

  • Supernus Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SUPN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2021 (DEF 14A).

Free

Get James Kelly’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

James Kelly compensation by year

Supernus Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Supernus Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$102,910
Bonus$0
Stock awards$0
Option awards$1,641,727
Non-equity incentive$50,900
Pension and deferred compensation$0
All other$6,099
Total$1,801,636

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Supernus Pharmaceuticals, Inc. DEF 14A filed April 30, 2021, accession 0001104659-21-058739, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Supernus Pharmaceuticals, Inc. filed document, accession 0001104659-21-058739. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option135,000—$21.13

Per the Outstanding Equity Awards at Fiscal Year-End table in Supernus Pharmaceuticals, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Supernus Pharmaceuticals’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Jack KhattarChief Executive Officer, President & Secretary$6,669,046
James Kelly · this pageFormer Executive Vice President, Chief Financial Officer$1,801,636
Stefan SchwabeExecutive Vice President of Research and Development, Chief Medical Officer$1,189,554
Gregory PatrickSenior Vice President, Chief Financial Officer$1,152,802
Padmanabh BhattSenior Vice President, Intellectual Property, Chief Scientific Officer$1,074,490
Tami MartinSenior Vice President, Regulatory Affairs$804,637

The full Supernus Pharmaceuticals compensation record

free company brief

This page is one person within Supernus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Supernus Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Supernus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

James Kelly's compensation dossier · One-time report. No refunds.